Improvements in symptoms related to bone metastasis in recipients of Lutetium-177 PSMA-617 for prostate cancer
Last Updated: Friday, July 17, 2026
Patient-reported outcome data—presented during the 2022 ASCO Genitourinary Cancers Symposium—among patients with metastatic castration-resistant prostate cancer receiving prostate-specific membrane antigen (PSMA) radioligand therapy (RLT) utilizing lutetium-177 show that patients reported reduced pain related to bone metastasis over time (P =.01). Further, among the 44 patients who completed the EORTC QLQ-BM22 before cycle 2, half reported clinically significant improvement in pain.
